Genocea Biosciences (GNCA) Sees Unusually-High Trading Volume After Better-Than-Expected Earnings

Shares of Genocea Biosciences Inc (NASDAQ:GNCA) saw unusually-strong trading volume on Thursday following a stronger than expected earnings report. Approximately 734,357 shares changed hands during mid-day trading, a decline of 1% from the previous session’s volume of 738,667 shares.The stock last traded at $0.66 and had previously closed at $0.64.

The biotechnology company reported ($0.09) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.10) by $0.01.

A number of equities research analysts have recently weighed in on the company. HC Wainwright set a $5.00 target price on Genocea Biosciences and gave the stock a “buy” rating in a research report on Thursday, August 2nd. Zacks Investment Research downgraded Genocea Biosciences from a “buy” rating to a “hold” rating in a research report on Tuesday, October 9th. Two analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The stock presently has an average rating of “Buy” and a consensus target price of $4.00.

Several hedge funds have recently added to or reduced their stakes in the company. California State Teachers Retirement System raised its position in shares of Genocea Biosciences by 166.6% during the first quarter. California State Teachers Retirement System now owns 125,569 shares of the biotechnology company’s stock worth $132,000 after acquiring an additional 78,469 shares during the last quarter. Schwab Charles Investment Management Inc. bought a new stake in shares of Genocea Biosciences during the first quarter worth $177,000. LMR Partners LLP bought a new stake in shares of Genocea Biosciences during the second quarter worth $175,000. DRW Securities LLC bought a new stake in shares of Genocea Biosciences during the second quarter worth $205,000. Finally, Paloma Partners Management Co bought a new stake in shares of Genocea Biosciences during the second quarter worth $343,000. Institutional investors own 60.23% of the company’s stock.

The company has a debt-to-equity ratio of 0.95, a current ratio of 6.84 and a quick ratio of 6.84.

Genocea Biosciences Company Profile (NASDAQ:GNCA)

Genocea Biosciences, Inc, a biopharmaceutical company, discovers and develops novel cancer vaccines. The company uses its proprietary discovery platform, ATLAS, to recall a patient's pre-existing CD4+ and CD8+ T cell immune responses to tumor to identify antigens for inclusion in vaccines that are designed to act through T cell (or cellular) immune responses.

Featured Story: Diversification Important in Investing

Receive News & Ratings for Genocea Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genocea Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply